Extract from the above information

By destroying the normal metabolic process of intracellular folate dependence, it inhibits cell replication and thus inhibits tumor growth. Pemetrexed can inhibit the activity of thymidylate synthase, dihydrofolate reductase and glycinamide nucleotide formyltransferase, and participate in the bioresynthesis of thymine nucleotides and purine nucleotides. The half-life of polyglutamic acid metabolites in tumor cells is prolonged, thereby prolonging the duration of drug action in tumor cells. Preclinical studies have shown that pemetrexed can inhibit the growth of mesothelioma cell lines (MSTO-211H, NCI-H2052) in vitro. Studies on the mesothelioma cell line MSTO-211H have shown that pemetrexed and cisplatin have a synergistic effect.

Pemetrexed is an antifolate preparation with a core pyrrolopyrimidine group in its structure. It inhibits cell replication and thus tumor growth by destroying the normal metabolic process of intracellular folate dependence. In vitro studies have shown that pemetrexed can inhibit the activity of thymidylate synthase, dihydrofolate reductase and glycinamide nucleotide formyltransferase, which are enzymes necessary for the synthesis of folate and participate in the bioresynthesis of thymine nucleotides and purine nucleotides. Pemetrexed enters the cell through the carrier carrying folic acid and the folate binding protein transport system on the cell membrane. Once pemetrexed enters the cell, it is converted into polyglutamate under the action of folylpolyglutamate synthetase. Polyglutamate remains in the cell and becomes an inhibitor of thymidylate synthase and glycinamide nucleotide formyltransferase. Polyglutamate is a time-concentration dependent process in tumor cells, while the concentration in normal tissues is very low. The half-life of polyglutamate metabolites in tumor cells is prolonged, thereby prolonging the action time of the drug in tumor cells. Preclinical studies have shown that pemetrexed can inhibit the growth of mesothelioma cell lines (MSTO-211H, NCI-H2052) in vitro. Studies on the mesothelioma cell line MSTO-211H have shown that pemetrexed combined with cisplatin has a synergistic effect.

No specific pharmacological effects mentioned

It promotes bile secretion, relaxes the terminal sphincter of the bile duct, reduces the tension of the duodenum, regulates the pressure of the bile duct system, and promotes the smooth entry of bile into the duodenum and the discharge of stagnant bile into the intestine; at the same time, it takes small stones, bacteria and their metabolites, and inflammatory exudates out of the bile duct, thereby eliminating inflammation and the pain it causes.

No specific pharmacological effects mentioned